Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13376985 | 0.90 | HDAC6 (0.40) | HDAC6HDAC1HDAC2 | |
| SCHEMBL2833822 | 0.77 | HDAC1 (0.30) | HDAC6HDAC1HDAC2 | |
| SCHEMBL752426 | 0.75 | GBA1 (0.33) | HDAC6HDAC1HDAC2 | |
| SCHEMBL752845 | 0.71 | HDAC3 (0.44) | HDAC1HDAC2 | |
| SCHEMBL1876097 | 0.69 | BACE1 (0.31) | — | |
| SCHEMBL753090 | 0.68 | TDP1 (0.44) | — | |
| SCHEMBL13376984 | 0.67 | HDAC6 (0.35) | HDAC6HDAC1HDAC2 | |
| SCHEMBL10227979 | 0.66 | HDAC6 (0.36) | HDAC6HDAC1HDAC2 | |
| SCHEMBL752427 | 0.66 | TDP1 (0.49) | — | |
| SCHEMBL8173526 | 0.66 | HDAC6 (0.40) | HDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093817-A1 | Compounds | BIAL - PORTELA & CA S.A. (PT) | 2010-04-15 | — | — | US | disclosed |
| EP-2121668-A2 | 6,8-DICHLORCHROMAN-3-YL-1,3-DIHYDROIMIDAZOLE-2-THIONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | BIAL - Portela & Ca., S.A. (PT) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008094054-A2 | 6, 8-DICHLORCHROMAN-3-YL-L, 3-DIHYDROIMIDAZOLE-2-THIONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | BIAL-PORTELA & CA, S.A. (PT) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093817-A1 | Compounds | TPMT, CYP2C8, ABL1 | HDAC6 120/4885HDAC1 662/4885HDAC2 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.